Renal Cancer - Results from #2100

Pegilodecakin as Monotherapy or in Combination with anti‐PD‐1 or Tyrosine Kinase Inhibitor in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma: Final Results of Cohorts A, G, H and I of IVY Phase I Study March 31, 2021

Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection. March 31, 2021

A qualitative framework of non-selection factors for cytoreductive nephrectomy. March 31, 2021

Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series. March 30, 2021

Increased risk for renal cell carcinoma in end stage renal disease - a population-based case-control study. March 30, 2021

AVEO Oncology Announces Addition of Tivozanib into National Comprehensive Cancer Network Clinical Practice Guidelines March 29, 2021

Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. March 29, 2021

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). March 29, 2021

Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. March 26, 2021

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. March 26, 2021

Hypoxia-induced microRNA-155 overexpression in extracellular vesicles promotes renal cell carcinoma progression by targeting FOXO3. March 25, 2021

Application of diffusion kurtosis tensor MR imaging in characterization of renal cell carcinomas with different pathological types and grades. March 25, 2021

Safety and oncological outcome following radiofrequency ablation of small renal masses in a single center. March 24, 2021

Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. March 24, 2021

Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. March 23, 2021

What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. March 23, 2021

Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. March 22, 2021

Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? March 22, 2021

Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'. March 22, 2021

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. March 19, 2021

Page 106 of 456